Loading ...
to show the noninferiority of iFR to FFR , with respective noninferiority margins of 3.4 % and 3.2 % for the difference in risk(passive) were designedSWEDEHEART trials
World Heart Federation President Salim YusufleadsHope-3 trials
its officerssetonto trials
studies(passive) should ... are designedl trials
to assess the safety and effectiveness of an experimental therapy , to assess whether the new intervention is better than the standard therapy , or to simply compare how effective one already marketed drug is to another(passive) may be designedTrials
a wayto designtrials tha
to assess the safety and effectiveness of an experimental therapy , to assess whether the new intervention is better than the standard therapy , or to simply compare how effective one already marketed(passive) may be designedTrials
to assess the safety and efficacy of an experimental therapy , to assess whether the new intervention is better than standard therapy , or to compare the efficacy of two standard or marketed interventions(passive) may be designedTrials
the manufacturers of the creation and surprise , surprise(passive) lead byscurf trials
to assess the safety and efficacy of an experimental therapy , to assess whether the new intervention is better than standard therapy , or to compare the efficacy of two standard or marketed(passive) may be designedTrials
to show that an alternative treatment is not substantially worse than the standard intervention(passive) are designedNoninferiority trials
to treat a certain stage of cancer , either as the first form of treatment offered , or as an option for treatment after other treatments have failed to work(passive) are often designedTrials
to demonstrate a drug?s safety and effectiveness in a series of specific cases(passive) may be designedTrials
up ... Canadian doctors , using Canadian test subjects , to determine if a drug is safe in the United States market(passive) set ... bytrials
FactorsinfluencingPharmacogenomics trials
to test toxicity of the drug and to attempt to establish a treatment dose(passive) were designedtrials
to address questions challenging in conventional preclinical models and early phase human trials(passive) are designedTrials
with only sufficient power to test the primary hypothesis in which case they will be inherently underpowered to determine whether individual characteristics of treatment might be associated with affect outcome(passive) are usually designedTrials
so that the patient , the treatment team , the outcome assessor , and even the trial statistician and any data monitoring committee are all blinded to the allocated treatment(passive) can be designedTrials
non - EORTC groups(passive) led byintergroup trials
to test for toxicity and side effects and/or to demonstrate whether the drug will have the desired effect(passive) are designedTrials
so that you will receive treatment whether you are on the experimental arm receiving the study drug or the placebo arm receiving the standard of care(passive) are designedTrials
to gauge how the court may react to evidence and testimony that is likely to be repeated throughout the litigation , with the goal of moving the overall litigation towards resolution(passive) are designedBellwether trials
to treat a certain stage of cancer , either as the first form of treatment offered , or as an option for treatment after other t(passive) are often designedTrials
to compare a new treatment to one or more standard treatments and are usually randomized(passive) are designedtrials
that courts will continueto setbellwether trials
to test the safety of the drug(passive) are also designedTrials
for a limited number of cases(passive) are setBellwether trials
to test the safety and efficacy of MyoCell in treating patients with severe , chronic damage to the center(passive) are already designedTrials
to test the safety and efficacy of MyoCell in treating patients with severe , chronic damage to the center(passive) are designedTrials
that the patient , the treatment team , the outcome assessor(passive) can be designed soTrials
to assess both the safety and effectiveness of a product(passive) are designedTrials
that authors of new randomised trials were often unaware of relevant reviewswhen designingtrials
large trials or investigatorsare designingtrials
to confirm the drug?s safety and determine its tolerability in humans(passive) are designedTrials
to look at the effects of a treatment on a single primary endpoint(passive) are designedTrials
to look at the effects of a treatment on a single primary endpoint(passive) are designed Trials
U.S. Food and Drug Administration Center for Drug Evaluation and Research statisticiansare designingtrials
that patients and the public can helpto designtrials
to evaluate a range of advanced statistical approachwhen designingtrials
to a curry pillcould leadto a curry pill
For Marketing PurposeDesigned MostlyFor Marketing Purpose
Mostly For Marketing PurposeDesignedMostly For Marketing Purpose
for hearingsetfor hearing
for its medicinal usesalready setfor its medicinal uses
the assignment of the company old agescausedthe assignment of the company old ages
to detect a small inconsequential benefitdesignedto detect a small inconsequential benefit
to provide robust evidence for sustained clinical benefits enabling clinicians to determine the optimal treatment strategy for individual patientsdesignedto provide robust evidence for sustained clinical benefits enabling clinicians to determine the optimal treatment strategy for individual patients
using these techniques may not accurately reflect actual patient populations leading to trial recruitment difficulties , erroneous trial outcomes or unexpected post - approval therapy performancedesignedusing these techniques may not accurately reflect actual patient populations leading to trial recruitment difficulties , erroneous trial outcomes or unexpected post - approval therapy performance
to assess blood pressure in responders rather than all randomised patients , ( iv ) trials using a second on - trial randomisation that re - assigned some active arm patients to placebo treatment , ( v ) trialdesignedto assess blood pressure in responders rather than all randomised patients , ( iv ) trials using a second on - trial randomisation that re - assigned some active arm patients to placebo treatment , ( v ) trial
to gauge how juries may respond to certain evidence and testimony that may be repeated throughout hundreds of Bard IVC filter lawsuits pending in the federal court systemdesignedto gauge how juries may respond to certain evidence and testimony that may be repeated throughout hundreds of Bard IVC filter lawsuits pending in the federal court system
to begin over this summersetto begin over this summer
and conducted in accordance with existing guidelines of the International Headache Society ( IHS ) for controlled studies of pharmacological therapiesdesignedand conducted in accordance with existing guidelines of the International Headache Society ( IHS ) for controlled studies of pharmacological therapies
to determine which products to treat a given condition are the most effective?as well as cost - effective?for various patient populationsare designedto determine which products to treat a given condition are the most effective?as well as cost - effective?for various patient populations
to test the effects of interactions between person - level characteristics and the treatment effectdesignedto test the effects of interactions between person - level characteristics and the treatment effect
to assess the clinical efficacy of this treatment strategydesignedto assess the clinical efficacy of this treatment strategy
a significant clinical improvement in patients with no difference in mortalityleada significant clinical improvement in patients with no difference in mortality
to assess primary effects on cardiovascular outcomes , and important between - study heterogeneity preclude definitive conclusionsdesigned specificallyto assess primary effects on cardiovascular outcomes , and important between - study heterogeneity preclude definitive conclusions
to assess the safety of a drug , procedure , or device ( the treatmentdesignedto assess the safety of a drug , procedure , or device ( the treatment
to test drug effectiveness and safety in humansdesignedto test drug effectiveness and safety in humans
to new cancer drug approvals worldwidehave ... ledto new cancer drug approvals worldwide
in mass trials [ and ] mass death sentenceshave resultedin mass trials [ and ] mass death sentences
to registration of novel agents and that randomized patients to placebo or best supportive careledto registration of novel agents and that randomized patients to placebo or best supportive care
to the drugs ' approval for medical usecould ... leadto the drugs ' approval for medical use
to US Food and Drug Administration ( FDA ) cancer drug approvalsleadingto US Food and Drug Administration ( FDA ) cancer drug approvals
to evaluate its effectiveness not only in significant reduction in cancer mortality , but also of ... other distinct endpointsdesignedto evaluate its effectiveness not only in significant reduction in cancer mortality , but also of ... other distinct endpoints
significant clinical or statistical heterogeneity in the datacausesignificant clinical or statistical heterogeneity in the data
to assess chemotherapy benefit in node - negative patients with Recurrence Score results between 12 and 25 and node - positive patients with results 25 , respectivelywere designedto assess chemotherapy benefit in node - negative patients with Recurrence Score results between 12 and 25 and node - positive patients with results 25 , respectively
to test non - inferiority or equivalence of two pain treatmentsdesignedto test non - inferiority or equivalence of two pain treatments
to test the efficacy of a therapeutic interventionprimarily designedto test the efficacy of a therapeutic intervention
to obtain the approval of the FDA for the drug to be sold commercially for a given diseasedesignedto obtain the approval of the FDA for the drug to be sold commercially for a given disease
to measure dose responses or treatment efficacy in subjects with ADHDdesignedto measure dose responses or treatment efficacy in subjects with ADHD
us to push ourselves and thus , strengthen our faith as a result if we turn to God and allow Him to change usoften causeus to push ourselves and thus , strengthen our faith as a result if we turn to God and allow Him to change us
to test the drug?s efficacydesignedto test the drug?s efficacy
to support approval of a specific therapeutic product and a specific companion diagnosticdesignedto support approval of a specific therapeutic product and a specific companion diagnostic
to registration of novel agents and that randomized patients to placebo or best supportive care were excludedledto registration of novel agents and that randomized patients to placebo or best supportive care were excluded
to detect overall treatment effectsdesignedto detect overall treatment effects
to test and spur Christians on in their walk with Christ ( With God , all things are possible , including trialsare ... designedto test and spur Christians on in their walk with Christ ( With God , all things are possible , including trials
to establish whether an experimental treatment is superior to a controldesignedto establish whether an experimental treatment is superior to a control
to show whether they really put God firstdesignedto show whether they really put God first